Novartis Secures FDA Approval for Cosentyx in Polymyalgia Rheumatica Following Positive Phase 3 Results

18 November 2026 | Wednesday | News

The FDA has approved Cosentyx (secukinumab) for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate steroid tapering. The approval marks the drug’s 11th US indication and follows Phase 3 REPLENISH trial results showing doubled sustained remission rates and reduced reliance on steroids compared with placebo
Image Source: Public Domain

Image Source: Public Domain

Cosentyx (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹

Approval marks 11th US indication for Cosentyx, building on its decade-long established efficacy and safety profile across immune-mediated diseases¹

Cosentyx PMR indication already approved in EU; additional regulatory reviews ongoing, including in Japan

Novartis announced that the US Food and Drug Administration (FDA) approved Cosentyx (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.¹ Cosentyx is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for people living with PMR, a common inflammatory disease that primarily affects adults over 50, providing a new treatment option beyond long-term steroid use—the current standard of care, which may be associated with significant side effects and risks.¹⁻⁵

“The FDA approval of secukinumab in PMR marks a significant advancement for patients and physicians. Patients with PMR are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening,” said Prof. John Stone, MD, MPH, Professor of Medicine, Harvard Medical School, Massachusetts General Hospital, and global principal investigator for the REPLENISH trial. “For too long, treatment options beyond glucocorticoids have been limited. In the Phase III REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment.”

In the United States, there are approximately 966,000 people living with PMR—a disease characterized by acute pain and stiffness in the shoulders, neck, and hips.²˒⁶ PMR is commonly treated with steroids, but relapses are frequent, affecting up to 40% of patients in the first year.⁴ Long-term steroid use increases the risk of osteoporosis, cardiovascular disease, and diabetes.³ The approval of Cosentyx as the first anti-IL-17 biologic indicated for people with PMR offers rheumatologists an alternative to long-term steroid use based on more than a decade of clinical experience across immune-mediated diseases.¹

“PMR can make remarkably ordinary things hard: getting out of bed, getting dressed, lifting your arms, getting through the day. For years, patients have had too few treatment options,” said Seth Ginsberg, Co-Founder and President, Global Healthy Living Foundation and CreakyJoints. “The approval of secukinumab offers patients and their clinicians a new therapeutic option and the opportunity for more individualized care.” 

“For more than a decade, Cosentyx has helped redefine what’s possible for people living with immune-mediated diseases, delivering meaningful outcomes across multiple conditions,” said Victor Bultó, President, US, Novartis. “With this approval in PMR, our 11th US indication for Cosentyx, we are expanding those benefits to a community that has had limited treatment options for far too long. This milestone reflects our commitment to continually investigate where our medicines can help patients most, extending the impact of proven innovations to new areas of significant unmet need.”

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close